Full Press Release Details
dupixent dupilumab demonstrates potential to become first biologic to treat copd by showing significant reduction in exacerbations in pivotal trial.
REGN
dupixent dupilumab demonstrates potential to become first biologic to treat copd by showing significant reduction in exacerbations in pivotal trial
Key Takeaway: dupixent dupilumab demonstrates potential to become first biologic to treat copd by showing significant reduction in exacerbations in pivotal trial